News

TransUnion Achieves Robust Growth with New Buyback Plan

TransUnion Achieves Robust Growth with New Buyback Plan

TransUnion Reports Impressive Fourth Quarter Results

TransUnion (NYSE: TRU) has announced a stellar performance for its fourth quarter, achieving a revenue milestone of $1.037 billion. This reflects a 9% increase compared to last year, surpassing analyst expectations of $1.027 billion.

Market Performance in Different Segments

In the U.S. market, revenue soared to $792 million, marking an 8% year-over-year growth. Meanwhile, the international segment saw an even more impressive growth of 11%, bringing in $245 million.

Focus on Adjusted EBITDA

TransUnion reported a significant boost in adjusted EBITDA, which rose by 16% year-over-year to $378 million. The adjusted EBITDA margin also improved, reaching 36%, up from 34% in the previous year. Furthermore, the adjusted earnings per share (EPS) of $0.97 also exceeded the analyst's forecast of $0.96.

Financial Strength Overview

For the past year, the company generated an operating cash flow of $832.5 million and recorded cash and cash equivalents of $679 million as of year-end.

Leadership’s Insights on Growth

President and CEO, Chris Cartwright, commented on the results, stating that U.S. Markets experienced high single-digit growth amid stable market conditions. Factors such as mortgage pricing and a boost in non-mortgage financial services aided this growth. Additionally, the international sector thrived, led by growth in India, Asia Pacific, and Latin America.

Dividend and Shareholder Returns

The Board has approved a cash dividend of $0.115 per share for the fourth quarter of 2024, set to be paid to shareholders by mid-March 2025. Additionally, they have initiated a share repurchase program worth up to $500 million, signaling strong confidence in the company’s future performance.

Future Outlook

Looking forward, TransUnion anticipates an adjusted EPS between $0.96 and $0.99 for the first quarter, which is below the consensus estimate of $1.05. The anticipated revenue for this quarter ranges from $1.06 billion to $1.074 billion, again slightly lower than street expectations of $1.096 billion.

Long-Term Projections

For the year 2025, the company expects adjusted EPS to fall between $3.93 and $4.08, competing with a consensus estimate of $4.46. Revenue projections are estimated at around $4.333 billion to $4.393 billion, compared to the market's expectation of $4.48 billion.

Innovative Consumer Offerings

Recently, TransUnion launched a new direct-to-consumer service in the U.S., partnering with Credit Sesame. This innovative initiative aims to provide users with a unique freemium credit education experience, closely associated with premium credit monitoring services. This is a strategic move to enhance consumer engagement across TransUnion's digital platforms.

Investment Opportunities

For investors looking to diversify their portfolio, shares of TransUnion can be accessed through ETFs such as the VanEck Morningstar Wide Moat Growth ETF (NYSE: MGRO) and the VanEck Morningstar ESG Moat ETF (NYSE: MOTE).

Current Price Performance

Recently, TransUnion (TRU) shares recorded a healthy uptick of 4.11% to settle at $97.31, indicating a positive market response following the news of its financial results and strategic plans.

Frequently Asked Questions

What were TransUnion's Q4 earnings?

TransUnion reported a fourth-quarter revenue of $1.037 billion, surpassing analyst estimates.

How much has TransUnion authorized for share buybacks?

The company has authorized a share repurchase program of up to $500 million.

What are the future projections for TransUnion's EPS?

For 2025, TransUnion expects adjusted EPS between $3.93 and $4.08.

Who is the President and CEO of TransUnion?

Chris Cartwright serves as the President and CEO of TransUnion.

What new services are being offered by TransUnion?

TransUnion launched a new direct-to-consumer credit education experience in collaboration with Credit Sesame.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 41

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 36

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 32

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 37

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Growth of Middle-Class Investors through Mutual Fund Ownership

Updated Category News Views 149

Mutual Funds and the Rise of the Middle-Class Investor Over recent years, mutual fund ownership has surged among middle-class families. According to insights from the Investment Company Institute (ICI), this trend signifies a vital transition as middle-income households increasingly seek investment opportunities. The growing presence of mutual funds in the American...

Continue Reading
Rques Exchange Reinforces Its Brand with Compliance Strategy

Updated Category News Views 180

Rques Exchange Reinforces Brand with Regulatory Frameworks Rques Exchange is taking significant steps to enhance its brand by emphasizing its commitment to regulatory alignment, operational transparency, and governance integrity in various markets. With global authorities increasingly scrutinizing digital asset platforms, Rques aims to position itself as a technology...

Continue Reading
Business Growth and Confidence: Provident Bank's Insights

Updated Category News Views 120

Increasing Business Confidence for the Future Recently, Provident Bank, a prominent financial institution based in New Jersey, conducted an enlightening Economic Outlook survey. This survey reflects the sentiments of 1,000 business leaders regarding the 2025 economic prospects. The results showcase a robust sense of optimism and confidence among businesses as they look...

Continue Reading
Performance Food Group Co: A Five-Year Stock Journey

Updated Category News Views 219

Unlocking the Value of Investment in Performance Food Group Co Performance Food Group Co (NYSE: PFGC) has delivered impressive returns over the last five years, standing out in the competitive market landscape. With an annualized return that has surpassed the market by 9.42%, investors have seen an average growth rate of around 24.5%. This stock is not just another entry...

Continue Reading
Understanding Rathbones Group Plc's Disclosure Requirements

Updated Category News Views 227

Key Information on Disclosure Requirements Understanding how companies disclose their shareholding is crucial for investors and stakeholders alike. Rathbones Group Plc plays an essential role in managing these disclosures, particularly regarding relevant securities that represent substantial interests in listed companies. Full Name of the Discloser The full name of the...

Continue Reading